Immunotherapy in colorectal cancer: for the select few or all?

被引：43

作者：

Arora, Sukeshi Patel ^{[1
]}

Mahalingam, Devalingam ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, 7979 Wurzbach Rd,MC8026, San Antonio, TX 78229 USA

来源：

JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2018年 / 9卷 / 01期

关键词：

Colorectal cancer (CRC); immunotherapy; checkpoint inhibition; programmed death-1 (PD-1); mismatch repair; ACTIVE SPECIFIC IMMUNOTHERAPY; III COLON-CANCER; PHASE-II; MICROSATELLITE INSTABILITY; IMMUNE MICROENVIRONMENT; RANDOMIZED-TRIAL; CELL VACCINE; STAGE-II; NIVOLUMAB; ANTIBODY;

D O I：

10.21037/jgo.2017.06.10

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past few years, the role of immunotherapy in colorectal cancer (CRC) has expanded, specifically in subsets of CRC with microsatellite instability (MSI) for which newer agents, such as programmed death-1 (PD-1) inhibitors, are efficacious. While other immunotherapeutic agents are more immature in development, they have the potential to enhance the efficacy of PD-1 inhibitors and play a role in the treatment algorithm for all subsets of CRC patients. In this review, we will discuss immunotherapeutic agents in development in patients with CRC. We will review the later phase studies that elucidate the role of immunotherapy in CRC and provide hope for changing the treatment paradigm for CRC in the future.

引用

页码：170 / 179

页数：10

共 60 条

[1] Peptide Vaccine Therapy in Colorectal Cancer [J].

Bartnik, Aleksandra ;

Nirmal, Ajit Johnson ;

Yang, Shi-Yu .

VACCINES, 2013, 1 (01) :1-16

[2] Metastatic Colon Cancer, Version 3.2013 [J].

Benson, Al B., III ;

Bekaii-Saab, Tanios ;

Chan, Emily ;

Chen, Yi-Jen ;

Choti, Michael A. ;

Cooper, Harry S. ;

Engstrom, Paul F. ;

Enzinger, Peter C. ;

Fakih, Marwan G. ;

Fenton, Moon J. ;

Fuchs, Charles S. ;

Grem, Jean L. ;

Hunt, Steven ;

Kamel, Ahmed ;

Leong, Lucille A. ;

Lin, Edward ;

May, Kilian Salerno ;

Mulcahy, Mary F. ;

Murphy, Kate ;

Rohren, Eric ;

Ryan, David P. ;

Saltz, Leonard ;

Sharma, Sunil ;

Shibata, David ;

Skibber, John M. ;

Small, William, Jr. ;

Sofocleous, Constantinos T. ;

Venook, Alan P. ;

Willett, Christopher G. ;

Gregory, Kristina M. ;

Freedman-Cass, Deborah A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (02) :141-152

[3] Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma [J].

Bilusic, Marijo ;

Heery, Christopher R. ;

Arlen, Philip M. ;

Rauckhorst, Myrna ;

Apelian, David ;

Tsang, Kwong Y. ;

Tucker, Jo A. ;

Jochems, Caroline ;

Schlom, Jeffrey ;

Gulley, James L. ;

Madan, Ravi A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (03) :225-234

[4] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] The effect of immune microenvironment on the progression and prognosis of colorectal cancer [J].

Chen, Jinxiang ;

Chen, Zihua .

MEDICAL ONCOLOGY, 2014, 31 (08)

[9] Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer [J].

Chung, Ki Y. ;

Gore, Ira ;

Fong, Lawrence ;

Venook, Alan ;

Beck, Stephen B. ;

Dorazio, Prudence ;

Criscitiello, Peggy J. ;

Healey, Diane I. ;

Huang, Bo ;

Gomez-Navarro, Jesus ;

Saltz, Leonard B. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) :3485-3490

[10] Microsatellite Instability as a Biomarker for PD-1 Blockade [J].

Dudley, Jonathan C. ;

Lin, Ming-Tseh ;

Le, Dung T. ;

Eshleman, James R. .

CLINICAL CANCER RESEARCH, 2016, 22 (04) :813-820

← 1 2 3 4 5 6 →